Please use this identifier to cite or link to this item:
Title: Fibronectin expression is decreased in metastatic renal cell carcinoma following endostatin gene therapy
Authors: CHAVES, Karen Cristina BarbosaTURACA, Lauro ThiagoPESQUERO, Joao BoscoMENNECIER, GregoryDAGLI, Maria Lucia ZaidanCHAMMAS, RogerSCHOR, NestorBELLINI, Maria Helena
Citation: BIOMEDICINE & PHARMACOTHERAPY, v.66, n.6, p.464-468, 2012
Abstract: Tumor cells induce the disruption of homeostasis between cellular and extracellular compartments to favor tumor progression. The expression of fibronectin (FN), a matrix glycoprotein, is increased in several carcinoma cell types, including renal cell carcinoma (RCC). RCC are highly vascularized tumors and are often amenable to antiangiogenic therapy. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we examined the modulation of FN gene expression by ES gene therapy in a murine metastatic renal cell carcinoma (mRCC) model. Balb/C mice bearing Renca cells were treated with NIH/3T3-LXSN cells or NIH/3T3-LendSN cells. At the end of the experiment, the ES serum levels were measured, and the FN gene expression was assessed using real-time PCR. The tissue FN was evaluated by western blotting and by immunofluorescence analysis. The ES serum levels in treated mice were higher than those in the control group (P < 0.05). ES treatment led to significant decreases at the FN mRNA (P < 0.001) and protein levels (P < 0.01). Here, we demonstrate the ES antitumor effect that is mediated by down-regulation of FN expression in mRCC.
Appears in Collections:Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)509.69 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.